




PHARMACEUTICAL 2021

VYNE Therapeutics Inc.
Rank 364 of 402





RealRate

PHARMACEUTICAL 2021

VYNE Therapeutics Inc. Rank 364 of 402



The relative strengths and weaknesses of VYNE Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VYNE Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 13% points. The greatest weakness of VYNE Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 218% points.

The company's Economic Capital Ratio, given in the ranking table, is -256%, being 303% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	87,259
Cost of Goods Sold	1,392
Intangible Assets	0
Liabilities, Current	21,453
Liabilities, Non-Current	34,796
Other Assets	5,928
Other Compr. Net Income	-5.0
Other Expenses	141,811
Other Liabilities	0
Other Net Income	-1,110
Other Revenues	20,993
Property and Equipment	555
Research and Development	43,533
Selling, General and Administrative Expense	89,543

Output Variable	Value in 1000 USD
Assets	93,742
Liabilities	56,249
Expenses	276,279
Revenues	20,993
Stockholders Equity	37,493
Net Income	-256,396
Comprehensive Net Income	-256,398
Economic Capital Ratio	-256%